Skip to content

Medical emergency? What to do

Triple therapy useful for blindness disorder

3-RXPublished June 28, 20072 min read

Key points

  • A single session of photodynamic therapy plus injections of the drugs bevacizumab (Avastin) and triamcinolone into the eye may improve or stabilize the vision of patients with neovascular age-related macular degeneration (AMD), a study shows.
  • The study was designed based on the hypothesis that the combination of photodynamic therapy and injections of bevacizumab and triamcinolone could interrupt the pathway leading to AMD, Dr.
  • In the study, 17 eyes with neovascular AMD were treated with single-session photodynamic therapy according to the standard protocol.
  • Vision improved in 11 eyes and remained unchanged in 6 eyes 12 weeks after initial treatment.

A single session of photodynamic therapy plus injections of the drugs bevacizumab (Avastin) and triamcinolone into the eye may improve or stabilize the vision of patients with neovascular age-related macular degeneration (AMD), a study shows.

AMD is the most common cause of blindness in adults 55 years of age and older. Neovascular or "wet" AMD accounts for just 8 percent of cases, but is responsible for 85 percent of the severe vision loss caused by the disease. Photodynamic therapy, a popular treatment for the condition, uses light energy to reduce the abnormal blood vessel formation that occurs in the disease.

The study was designed based on the hypothesis that the combination of photodynamic therapy and injections of bevacizumab and triamcinolone could interrupt the pathway leading to AMD, Dr. Hamid Ahmadieh of Labbafinejad Medical Center, Tehran, Iran, told Reuters Health.

"We limited photodynamic therapy to one session in our treatment protocol to reduce the cost of treatment and the potential side effects of photodynamic therapy," Ahmadieh explained.

In the study, 17 eyes with neovascular AMD were treated with single-session photodynamic therapy according to the standard protocol. This was followed by injections of bevacizumab and triamcinolone 48 hours later.

Significant improvements in vision were noted in most eyes at 12 and 24 weeks, the authors report in the journal BioMedCentral (BMC) Ophthalmology.

Vision improved in 11 eyes and remained unchanged in 6 eyes 12 weeks after initial treatment. After 24 weeks, vision improved in 13 eyes and remained unchanged in 4.

A larger study is underway to confirm the results of this pilot study, Ahmadieh said.

SOURCE: BMC Ophthalmology, June 7th online issue 2007.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.